Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase 2 randomised, double-blind BOLT study.

CONCLUSIONS: Sonidegib demonstrated sustained efficacy and a manageable safety profile. Final BOLT results support sonidegib as a viable treatment option for laBCC and mBCC.
PMID: 31545507 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - September 22, 2019 Category: Dermatology Authors: Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, Combemale P, Dirix L, Kaatz M, Kudchadkar R, Loquai C, Plummer R, Schulze HJ, Stratigos AJ, Trefzer U, Squittieri N, Migden MR Tags: Br J Dermatol Source Type: research